The first activation study of the $\beta$-carbonic anhydrases from the pathogenic bacteria Brucella suis and Francisella tularensis with amines and amino acids

Andrea Angelib, Sonia Del Preteb, Mariana Pintealac, Stelian S. Maierc,d, William A. Donalde, Bogdan C. Simionescuc, Clemente Capassoa,cd and Claudiu T. Supuranb,ef

aNeurofarba Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Sesto Fiorentino, Italy; bIstituto di Bioscienze e Biorisorse, CNR, Napoli, Italy; cCentre of Advanced Research in Bionanocojnguates and Biopolymers Department, “Petru Poni” Institute of Macromolecular Chemistry, Iasi, Romania; dPolymers Research Center, Polymeric Release Systems Research Group, “Gheorghe Asachi” Technical University of Iasi, Iasi, Romania; eSchool of Chemistry, University of New South Wales, Sydney, Australia

ABSTRACT
The activation of the $\beta$-class carbonic anhydrases (CAs, EC 4.2.1.1) from the bacteria Brucella suis and Francisella tularensis with amine and amino acids was investigated. BsucA 1 was sensitive to activation with amino acids and amines, whereas FtuCA was not. The most effective BsucA 1 activators were L-adrenaline and D-Tyr ($K_a$ of 0.70–0.95 M). L-His, L-/D-Phe, L-/D-DOPA, L-Trp, L-Tyr, 4-amino-L-Phe, dopamine, 2-pyridyl-methylamine, D-Glu and L-Gln showed activation constants in the range of 0.70–3.21 M. FtuCA was sensitive to activation with L-Glu ($K_a$ of 9.13 M). Most of the investigated compounds showed a weak activating effect against FtuCA ($K_a$ of 30.5–78.3 M). Many of the investigated amino acid and amines are present in high concentrations in many tissues in vertebrates, and their role in the pathogenicity of the two bacteria is poorly understood. Our study may bring insights in processes connected with invasion and pathogenic effects of intracellular bacteria.

1. Introduction
The pathogenic bacteria Brucella suis1,2 and Francisella tularensis3,4 provoke serious diseases both in human and livestock, are difficult to treat by antibiotics, and have the potential to induce widespread infections. In fact, both Brucella and Francisella might be used as bioterrorism organisms due to the fact that quite low doses of pathogens (as few as 10–100 bacteria) are highly infectious, leading to ravaging epidemics1. Furthermore, they persist in the environment and are rapidly transmitted via different routes, including by aerosols and from human to human1. Brucellosis, like tularemia (the infection produced by F. tularensis) are neglected diseases, although their prevalence in humans and domestic/wild animals is not at all low1–4. These pathogens also became resistant to many currently used antibiotics3–4, with the danger that the treatment of infected patients/animals will become increasingly difficult. Thus, searching for new drug targets addressing these complex issues is of stringent relevance.

Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes in all kingdoms5–7. They catalyze the reversible hydration of CO$_2$ with formation of bicarbonate and protons, converting thus efficiently two neutral molecules (CO$_2$ and H$_2$O) in a weak base (bicarbonate) and a very strong acid (H$^+$ ions)5–10. For this reason, in most organisms investigated so far, from simple (such as bacteria and archaea) to complex ones (plants, animals etc.) these enzymes are involved in pH regulation as well as several crucial metabolic pathways5–7,11–17. At least seven distinct CA genetic families are known to date ($\alpha$, $\beta$, $\gamma$, $\zeta$, $\eta$ and $\theta$-CAs)5–7, and their diffusion and physiological roles have been investigated in details mainly in vertebrates, including humans, who posses only $\alpha$-CAs, but with quite a large number of isoforms (15 CA isoforms are known in humans, human carbonic anhydrase (hCA) I-XIV, with two V-type ones, CA VA and VB)5. The investigation of CAs belonging to other classes, such as those found in bacteria, is on the other hand a rather recent field, although notable advances were registered in the last few years5,7,13,18,19. CA inhibitors (CAIs) belonging to many diverse chemotypes and possessing a wealth of inhibition mechanisms5–7 are clinically used for the management of a variety of disorders, including edema, epilepsy, glaucoma, obesity, hypoxic tumors, neuropathic pain and arthritis5–7,11,17. On the other hand, CA activators (CAAs) started to be investigated in detail only in the last two decades, after the CA activation mechanism has been explained by one of our groups5–10.

Indeed, CAAs have been demonstrated to participate in the CA catalytic cycle8, which is shown schematically in Equations (1) and (2) below:

$$\text{EZn}^{2+} + \text{OH}^- + \text{CO}_2 \iff \text{EZn}^{2+} + \text{HCO}_3^-(\text{H}_2\text{O}) \iff \text{EZn}^{2+} + \text{OH}_2 + \text{HCO}_3^-$$

(1)

$$\text{EZn}^{2+} + \text{OH}_2 \iff \text{EZn}^{2+} + \text{H}^+ + \text{HCO}_3^-$$

(2)

In the first step, a zinc-bound hydroxide species of the enzyme with a strong nucleophilicity, attacks the CO$_2$ substrate, which is weakly bound in a hydrophobic pocket nearby, being optimally oriented for the hydration reaction to occur by the attack of the zinc hydroxide nucleophile (Equation 1)8. In the next step of the
process, the formed bicarbonate in the hydration reaction is replaced by an incoming water molecule, leading to the formation of an acidic enzymatic species, $\text{EZn}^{2+} - \text{OH}_2$ (Equation 1). In order to regenerate the zinc hydroxide species, a proton must be transferred from the (II)-bound water molecule to the external medium (Equation 2). This is also the rate-determining step of the entire catalytic cycle. In the presence of activators (A in Equation 3), this rate-determining step is facilitated by an additional proton release pathway, which involves the activator A bound within the enzyme active site. It should be noted that all CAAs known to date possess in their molecule protonatable moieties of the amine, carboxylate or imidazole type, with $pK_a$ values in the range of 5–8.

$$\text{EZn}^{2+} - \text{OH}_2 + A \leftrightarrow [\text{EZn}^{2+} - \text{OH}_2 - A] \leftrightarrow [\text{EZn}^{2+} - \text{HO}^- - \text{AH}^+]$$

$$\leftrightarrow \text{EZn}^{2+} - \text{HO}^- + \text{AH}^+ \text{enzyme} - \text{activator complexes} \quad (3)$$

By the formation of enzyme-activator complex (Equation 3), the proton transfer reaction becomes intramolecular, and is thus more rapid compared with the intermolecular process in which for example buffer molecules participate. CA activator complexes were thoroughly characterized for $\alpha$-CAs of human origin, such as hCA I and II, by means of kinetic and X-ray crystallographic techniques, which allowed the identification of the activator-binding site within the CA cavity. CA research involving various activators has been relatively neglected compared with that of CAs, only with a relatively limited number of studies focusing on activators of bacterial CAs. Recently, it has been demonstrated that such activators may have pharmacological applications for enhancing cognition, in the management of CA deficiencies, for therapy memory and for obtaining artificial tissues as well as for investigating the effects of endogenous amino acids and amines on CA activity.

Here we report the first activation study of the CAs investigated so far in the genome of the two pathogenic bacteria mentioned earlier. Indeed, B. suis encodes for two $\beta$-CAs, BsuCA1 and BsuCA2, whereas in the genome of F. tularensis only one such enzyme is present (again belonging to the $\beta$-CA class, FtuCA) which were cloned and characterized by some of us earlier. The inhibition of these enzymes with sulfonamide, anions and other derivatives was reported earlier, but no activation studies of the two enzymes are available in the literature. Here we report the first activation study of BsuCA 1 and FtuCA with a panel of amino acids and amines, known to act as CAAs for enzymes belonging to various other genetic families.

2. Materials and methods

2.1. Materials

Amino acids and amines 1–24 were commercially available, highest purity reagents from Sigma-Aldrich, Milan, Italy. BsuCA 1 and FtuCA were recombiant proteins produced as reported earlier by our groups.

2.2. CA enzyme activation assay

An Sx.18Mw-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic activity of various CA isozymes for CO$_2$ hydration reaction. Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Tris (pH 8.4) as buffer, and 0.1 M Na$_2$SO$_4$ (for maintaining constant ionic strength, which is not inhibitory against these enzymes), following the CA-catalyzed CO$_2$ hydration reaction for a period of 10 s at 25°C. The CO$_2$ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and activation constants. For each activator at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of activators (10 mM) were prepared in distilled-deionized water and dilutions up to 1 mM were done thereafter with the assay buffer. Activator and enzyme solutions were pre-incubated together for 15 min (standard assay at room temperature) prior to assay, in order to allow for the formation of the E-A complex. The activation constant ($K_a$), defined similarly with the inhibition constant $K_i$ can be obtained by considering the classical Michaelis–Menten equation (Equation 4), which has been fitted by non-linear least squares by using PRISM 3:

$$v = \frac{v_{\text{max}}}{1 + \frac{[S]}{K_M}(1 + \frac{[A_i]}{K_a})}, \quad (4)$$

where $[A_i]$ is the free concentration of activator.

Working at substrate concentrations considerably lower than $K_M ([S] \ll K_M)$ and considering that $[A_i]$ can be represented in the form of the total concentration of the enzyme ([E]$_t$) and activator ([A]$_t$), the obtained competitive steady-state equation for determining the activation constant is given by Equation (5):

$$v = v_0.K_a \left( \frac{[A]_t - 0.5 \left( ([A]_t + [E]_t + K_a) - ([A]_t + [E]_t + K_a)^2 - 4[A]_t[E]_t \right)^{1/2}}{[E]_t} \right), \quad (5)$$

where $v_0$ represents the initial velocity of the enzyme-catalyzed reaction in the absence of activator. The results obtained with this type of kinetic assay are in excellent agreement with those obtained by use of other independent methods, including native mass spectrometry and fluorescence spectroscopy.

3. Results and discussion

Natural and non-natural amino acids and amines 1–24 were included among the investigated compounds as activators of the two bacterial $\beta$-CAs investigated here (Figure 1). These compounds were employed for investigations as CAAs against many classes of CAs, including the bacterial, archaeal and mammalian ones, as mentioned earlier. The salient feature of these compounds is the presence of protonatable moieties of the amine, carboxylate or imidazole type, which makes them appropriate for participating in the proton shuttling processes between the active site and the reaction medium, as described by Equation (3).

Data of Table 1 demonstrate that the two bacterial $\beta$-CAs investigated here shows a more effective CO$_2$ hydrase activity compared with hCA I, a widely spread isoform in humans. Considering the $K_{\text{act}}$, BsuCA 1 is 3.2-times more effective as a catalyst for CO$_2$ hydration compared with hCA I, whereas FtuCA is even more active, being 4.9-times more effective compared with the human enzyme. On the other hand, the Michaelis constants ($K_M$) of the bacterial enzymes are higher compared with the two human enzymes showed in Table 1 for comparison reasons. In fact the Michaelis constant of hCA I and II is in the range of 4.0–9.3 mM, whereas for the bacterial enzymes the $K_M$ values are in the range of 11.0–16.4 mM, denoting that CO$_2$ has a lower affinity for the bacterial enzymes than for the human ones hCA I/II. We have chosen L-Trp for performing detailed kinetic measurements because this amino acid was a rather
effective activator for both enzymes investigated here (as well as the human isoforms hCA I and II used as standard enzymes in such experiments – see Section 3). In the presence of 10 \( \mu M \) L-Trp as activator, the \( K_M \) of BsuCA 1/FtuCA remained unchanged (data not shown) but the \( k_{cat} \) was 4.60 times higher than in the absence of the activator for BsuCA 1, and 1.60-times higher for FtuCA, respectively (Table 1). This situation, in which the \( K_M \) does not depend on the presence of an activator and \( k_{cat} \) is strongly affected by the activator, has been observed for all CAs investigated to date, belonging to all known CA genetic families. This strongly indicates that the CA activation mechanism is similar for all enzyme classes, involving facilitation of the proton transfer process by the activator molecule bound within the enzyme active site in the enzyme-activator complex\textsuperscript{8–10}. It should be also noted that L-Trp is a much more effective activator for BsuCA 1 than for FtuCA (see Section 3).

In Table 2 the activation constants (\( K_A \)) of the bacterial \( \beta \)-CAs investigated here (BsuCA 1 and FtuCA) and of the human isoforms hCA I and II, with the amino acid and amine derivatives 1–24 (Figure 1) are shown. The human CA activation data are reported for comparison reasons.

Data of Table 2 show the following interesting features for the activation of BsuCA 1 and FtuCA with amino acid and amine derivatives 1–24:

1. The enzyme from \( B. suis \), BsuCA 1 was generally rather sensitive to activation with amino acids and amines of type 1–24, with activation constants in the range of 0.70–43.1 \( \mu M \). On the contrary, 13 out of the 24 compounds investigated here were inactive as activators of FtuCA (\( K_A > 100 \mu M \)), only one compounds had a \( K_A < 10 \mu M \) (L-Glu, 22), and most of the investigated active compounds showed a weak activating effect, with \( K_A \) ranging between 30.5 and

\[ \text{Table 1. Activation of hCA isozymes I, II and BsuCA 1/FtuCA, with L-Trp, at 25}^\circ \text{C, for the CO}_2 \text{hydration reaction}^{20}. \]

| Isozyme   | \( k_{cat} \) (s\(^{-1}\)) \( a \) | \( K_M \) (mM) \( a \) | \( (k_{cat}) \cdot \text{L-Trp} \) (s\(^{-1}\)) \( b \) | \( K_A \) (l\( \mu \)M) \( c \) | \( \text{L-Trp} \) |
|-----------|----------------|----------------|----------------|----------------|----------------|
| hCA I\(^ d \) | 2.0 \( \times 10^5 \) | 4.0 | 3.4 \( \times 10^3 \) | 44 | |
| hCA II\(^ d \) | 1.4 \( \times 10^5 \) | 9.3 | 4.9 \( \times 10^3 \) | 27 | |
| BsuCA 1\(^ e \) | 6.4 \( \times 10^5 \) | 16.4 | 25.9 \( \times 10^3 \) | 1.25 | |
| FtuCA\(^ e \) | 9.8 \( \times 10^5 \) | 11.0 | 15.7 \( \times 10^3 \) | 34.1 | |

\( a \)Observed catalytic rate without activator. \( K_M \) values in the presence and the absence of activators were the same for the various CAs (data not shown).
\( b \)Observed catalytic rate in the presence of 10 \( \mu M \) activator.
\( c \)The activation constant (\( K_A \)) for each enzyme was obtained by fitting the observed catalytic enhancements as a function of the activator concentration\textsuperscript{21–29}. Mean from at least three determinations by a stopped-flow, CO\(_2\) hydrase method\textsuperscript{30}. Standard errors were in the range of 5–10% of the reported values (data not shown).
\( d \)Human recombinant isozymes, from Supuran\textsuperscript{8a}.
\( e \)Bacterial recombinant enzyme, this work.

Figure 1. Amino acids and amines 1–24 investigated as activators.
Table 2. Activation constants of hCA I, hCA II and the bacterial β-CAs investigated here with amino acids and amines 1–24, by a stopped-flow CO2 hydrase assay.

| No. | Compound             | hCA Ib | hCA Ib | BsuCA1c | FtuCAc | K_A (μM)<sup>a</sup> |
|-----|----------------------|--------|--------|---------|--------|----------------------|
| 1   | L-His                | 0.03   | 10.9   | 1.76    | 40.7   |                     |
| 2   | D-His                | 0.09   | 43.3   | 12.3    | 78.3   |                     |
| 3   | L-Phe                | 0.07   | 0.013  | 1.16    | 69.1   |                     |
| 4   | D-Phe                | 86.0   | 0.035  | 1.21    | 75.0   |                     |
| 5   | L-DOPA               | 3.1    | 11.4   | 2.07    | <100   |                     |
| 6   | D-DOPA               | 4.9    | 7.8    | 2.34    | 44.8   |                     |
| 7   | L-Trp                | 44.7   | 27.7   | 1.25    | 34.1   |                     |
| 8   | D-Trp                | 41.2   | 12.3   | 13.7    | 30.5   |                     |
| 9   | L-Tyr                | 0.02   | 0.013  | 0.95    | <100   |                     |
| 10  | D-Tyr                | 0.04   | 0.013  | 1.38    | >100   |                     |
| 11  | 4-His,N-L-Phe        | 0.24   | 0.15   | 1.18    | >100   |                     |
| 12  | Histamine            | 2.1    | 125.1  | 3.71    | >100   |                     |
| 13  | Dopamine             | 13.5   | 9.20   | 1.54    | >100   |                     |
| 14  | Serotonin            | 45.0   | 50.0   | 4.26    | >100   |                     |
| 15  | 2-Pyridyl-methylamine| 26.4   | 34.2   | 1.62    | 46.3   |                     |
| 16  | 2-[L-Aminoethyl]pyridine| 13.0  | 15.0   | 5.20    | >100   |                     |
| 17  | I-[L-Aminoethyl]piperazine| 7.4   | 23.0   | 43.1    | 51.8   |                     |
| 18  | 4-[L-Aminoethyl]-morpholine| 0.14  | 0.19   | 9.56    | >100   |                     |
| 19  | L-Adrenaline         | 0.09   | 9.6    | 0.70    | >100   |                     |
| 20  | L-Asn                | 11.3   | >100   | 7.38    | >100   |                     |
| 21  | L-Asp                | 5.20   | >100   | 6.82    | >100   |                     |
| 22  | L-Glu                | 6.43   | >100   | 9.36    | 9.13   |                     |
| 23  | D-Glu                | 10.7   | >100   | 1.39    | >100   |                     |
| 24  | L-Gln                | >100   | >50.0  | 3.21    | 45.7   |                     |

<sup>a</sup>Mean from three determinations by a stopped-flow, CO2 hydrase method. Standard errors were in the range of 5–10% of the reported values (data not shown).
<br><sup>b</sup>Human recombinant isozymes, stopped flow CO2 hydrase assay method.
<br><sup>c</sup>Bacterial enzyme, this work.

4. Conclusions

The first activation study of the β-class CA enzymes from the pathogenic bacteria *B. suis* and *F. tularensis* is reported here. A panel of 24 amino acid and amine derivatives were included in the study. BsuCA 1 was sensitive to activation with amino acids and amines, which showed activation constants in the range of 0.70–43.1 μM. The most effective BsuCA 1 activators were L-adrenaline and D-Tyr (K_A of 0.70–0.95 μM), L-His, L-/D-Phe, L-/D-DOPA, L-Trp, L-Tyr, 4-amino-L-Phe, dopamine, 2-pyridyl-methylamine, D-Glu and L-Gln showed activation constants in the range of 0.70–3.21 μM. FtuCA was not sensitive to activation with many of the investigated compounds (K_A > 100 μM), and only L-Glu had a K_A < 10 μM. Most of the investigated active compounds showed a weak activating effect against FtuCA, with K_A ranging between 30.5 and 78.3 μM, such a L-/D-His, L-/D-Phe, L-/D-Trp, 2-pyridyl-methylamine. It should be noted that many of the investigated amino acid and amines are present in rather high concentrations in many tissues in vertebrates, and their role in the pathogenicity of the two bacteria is poorly understood. Our study may thus bring some insights in the intricate processes connected with the invasion and pathogenic effects of intracellular bacteria when attacking their hosts.

Acknowledgements

The Australian Research Council is also acknowledged for support.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was financially supported by a grant of the Romanian Ministry of Research and Innovation, CNCS-UEFISCDI, project number [PN-III-P4-ID-PCCF-2016–0050], within PNCDI III.

ORCID

Andrea Angeli http://orcid.org/0000-0002-1470-7192
Stelian S. Maier http://orcid.org/0000-0001-9929-2821
Clemente Capasso http://orcid.org/0000-0003-3314-2411
Claudiu T. Supuran http://orcid.org/0000-0003-4262-0323

References

1. a) El-Sayed A, Awad W. Brucellosis: evolution and expected comeback. Int J Vet Sci Med 2018;6(Suppl):S31–55; b) Dadar M, Shahali Y, Whatmore AM. Human brucellosis caused by raw dairy products: a review on the occurrence, major risk factors and prevention. Int J Food Microbiol 2019;292:39–47; c) Tuon FF, Gondolfo RB, Cerchiar N. Human-to-human transmission of Brucella - a systematic review. Trop Med Int Health 2017;22:539–46.
2. a) Hull NC, Schumaker BA. Comparisons of brucellosis investigated here with human and veterinary medicine. Infect Ecol Epidemiol 2018;8:1500846; b) Cross AR, Baldwin VM, Roy S, et al. Zoonoses under our noses. Microbes Infect 2019;21:10–9; c) Kühler S, Ouaharni-Bettache S, Winum JY. *Brucella suis* carbonic anhydrases and their inhibitors: towards
alternative antibiotics? J Enzyme Inhib Med Chem 2017;32: 683–7.

3. a) Hirschmann JV. From squirrels to biological weapons: the early history of tularemia. Am J Med Sci 2018;356:319–28; b) Pilo P. Phylogenetic lineages of Francisella tularensis in animals. Front Cell Infect Microbiol 2018;8:258.

4. a) Faber M, Heuner K, Jacob D, Grunow R. Tularemia in Germany—a re-emerging zoonosis. Front Cell Infect Microbiol 2018;8:40; b) Caspar Y, Maurin M. Francisella tularensis susceptibility to antibiotics: a comprehensive review of the data obtained in vitro and in animal models. Front Cell Infect Microbiol 2017;7:122.

5. a) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32; b) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:621–88; c) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81; d) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77; e) Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68.

6. a) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;30:325–32; b) Del Prete S, Vullo D, Fisher GM, et al. Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum—the 7-carbonic anhydrases. Bioorg Med Chem Lett 2014;24:4348–96; c) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72; d) Ozensoy Guler O, Capasso C, Supuran CT. A magnificant enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem 2016;31:689–94.

7. a) Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO2 capture. J Enzyme Inhib Med Chem 2013;28: 229–30; b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60; c) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68; d) Abbate F, Winum JY, Potter BV, et al. Carbonic anhydrase inhibitors: X-ray crystallographic study of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett 2004;14:231–4.

8. a) Supuran CT. Carbonic anhydrase activators. Future Med Chem 2018;10:561–73; b) Tanini D, Capperucci A, Supuran CT, Angeli A. Sulfur, selenium and tellurium containing amines act as effective carbonic anhydrase activators. Bioorg Chem 2019;87:516–22; c) Rami M, Winum JY, Poter BV, et al. Carbonic anhydrase inhibitors: X-ray crystallographic study of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett 2004;14:231–4.

9. a) Briganti F, Mangan S, Orioli P, et al., Carbonic anhydrase activators: x-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry 1997;36:10384–92; b) Clare B.W., Supuran C.T., Carbonic anhydrase activators. 3: structure-activity correlations for a series of isozyme II activators.

10. a) Akocak S, Lolak N, Vullo D, et al. Synthesis and biological evaluation of histamine Schiff bases as carbonic anhydrase I, II, IV, VII, and IX activators. J Enzyme Inhib Med Chem 2017;32:1305–12; b) Angeli A, Vaiano F, Mari F, et al. Psychoactive substances belonging to the amphetamine class potently activate brain carbonic anhydrase isoforms VA, VB, VII, and XII. J Enzyme Inhib Med Chem 2017;32:1253–9; c) Licsandru E, Tanc M, Kocsis I, Barboiu M, Supuran CT. A class of carbonic anhydrase I - selective activators. J Enzyme Inhib Med Chem 2017;32:37–46; d) Akocak S, Lolak N, Bua S, et al. α-Carbonic anhydrases are strongly activated by spinacemine derivatives. Bioorg Med Chem 2019;27:800–4.

11. a) Scozzafava A, Menabuoni L, Miscione F, Supuran CT. Carbonic anhydrase inhibitors: a general approach for the preparation of water-soluble sulfonamides incorporating polyamino – polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. J Med Chem 2002;45:1466–76; b) Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb) 2010;46:3731–3; c) Carta F, Scozzafava A, Supuran CT. Sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat 2012;22:747–58; d) Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001–10; e) Supuran CT, Clare BW. Carbonic anhydrase inhibitors. Part 57. Quantum chemical QSAR of a group of 1,3,4-thiadiazole and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties. Eur J Med Chem 1999;34:41–50.

12. a) Perfetto R, Del Prete S, Vullo D, et al. Cloning, expression and purification of the α-carbonic anhydrase from the mantle of the Mediterranean mussel, Mytilus galloprovincialis. J Enzyme Inhib Med Chem 2017;32:1029–35; b) Abdoli M, Angeli A, Bodzag M, et al. Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo[d]-thiazole-5- and 6-sulfonamides. J Enzyme Inhib Med Chem 2017;32:1071–8; c) De Simone G, Langella E, Esposito D, et al. Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations. J Enzyme Inhib Med Chem 2017;32:1002–11; d) Scozzafava A, Menabuoni L, Miscione F, et al. Carbonic anhydrase inhibitors: perfluorooalkyl-aryl substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J Med Chem 2002;45:4542–51.

13. a) Supuran CT, Capasso C. Carbonic anhydrase from Porphyromonas gingivalis as a drug target. Pathogens 2017; 6:E30; b) Capasso C, Supuran CT. Inhibition of bacterial carbonic anhydrases as a novel approach to escape drug resistance. Curr Top Med Chem 2017;17:1237–48; c) Supuran CT,
Capasso C. New light on bacterial carbonic anhydrases phylogeny based on the analysis of signal peptide sequences. J Enzyme Inhib Med Chem 2016;31:1254–60; d) Vullo D, Del Prete S, Di Fonzo P, et al. Comparison of the sulfonamide inhibition profiles of the β- and γ-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei. Molecules 2017;22:421–435; e) Prete SD, Vullo D, di Fonzo P, et al. Sulfonamide inhibition profile of the γ-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis. Bioorg Med Chem Lett 2017;27:490–5.

14. a) Supuran CT. Applications of carbonic anhydrase inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21; b) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12; c) Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013). Expert Opin Ther Pat 2013;23:737–49; d) Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869–73.

15. a) Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35; b) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48; c) Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Pat 2003;13:1545–50; d) Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31; e) Rehman SU, Chohan ZH, Gulnaz F, Supuran CT. In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. J Enzyme Inhib Med Chem 2005;20:333–40.

16. a) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–8; b) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebrovascular ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;31:894–9.

17. a) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31(suppl 4):60–3; b) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.

18. a) Del Prete S, Vullo D, Osman SM, et al. Anion inhibitors of the β-carbonic anhydrase from the pathogenic bacterium responsible of tularemia, Francisella tularensis. Bioorg Med Chem 2017;25:4800–4; b) Del Prete S, Vullo D, Osman SM, et al. Sulfonamide inhibition profiles of the β-carbonic anhydrase from the pathogenic bacterium Francisella tularensis responsible of the febrile illness tularemia. Bioorg Med Chem 2017;25:3555–61; c) Joseph P, Turtaut F, Ouahran-Bettache S, et al. Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.

J Med Chem 2010;53:2277–85; d) Joseph P, Ouahran-Bettache S, Montero JL, et al. A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorg Med Chem 2011;19:1172–8.

19. a) Angeli A, Del Prete S, Donald WA, et al. The γ-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae is potently activated by amines and amino acids. Bioorg Chem 2018;77:1–5; b) Angeli A, Del Prete S, Osman SM, et al. Activation studies with amines and amino acids of the β-carbonic anhydrase encoded by the Rv3273 gene from the pathogenic bacterium Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2018;33:364–9; c) Angeli A, Del Prete S, Osman SM, et al. Activation studies of the α- and β-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with amines and amino acids. J Enzyme Inhib Med Chem 2018;33:227–33; d) Vullo D, Del Prete S, Osman SM, et al. Comparison of the amine/amine acid activation profiles of the β- and γ-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei. J Enzyme Inhib Med Chem 2018;33:25–30; e) Vullo D, Del Prete S, Osman SM, et al. Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines. Bioorg Med Chem Lett 2016;27:77–80.

Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.

20. a) Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activation and the drug design. Curr Pharm Des 2008;14:708–715; b) Isik S, Guler O, Kockar F, et al. Saccharomyces cerevisiae β-carbonic anhydrase: inhibition and activation studies. Curr Pharm Des 2010;16:3327–36.

21. a) Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry 2006;12:7057–66; b) Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isoform II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem 2006;49:3019–27; c) Temperini C, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase activators: kinetic and X-ray crystallographic study for the interaction of D- and L-tryptophan with the mammalian isoforms I-IV. Bioorg Med Chem 2008;16:8373–8.

22. a) Temperini C, Innocenti A, Scozzafava A, et al. Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isoform II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg Med Chem Lett 2007;17:628–35; b) Temperini C, Scozzafava A, Puccetti L, Supuran CT. Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isoform II with L-histidine as a platform for the design of stronger activators. Bioorg Med Chem Lett 2005;15:5136–41; c) Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activators: the first X-ray crystallographic study of an adduct of isoform I. Bioorg Med Chem Lett 2006;16:5152–6.

23. a) Vullo D, Nishimori I, Innocenti A, et al. Carboxy anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines. J Med Chem 2010;53:2277–85; d) Joseph P, Ouahran-Bettache S, Montero JL, et al. A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorg Med Chem 2011;19:1172–8.
25. a) Parkkila S, Vullo D, Puccetti L, et al. Carbonic anhydrase activators: activation of isozyme XIII with amino acids and amines. Bioorg Med Chem Lett 2006;16:3955–9; b) Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. Bioorg Med Chem Lett 2007;17:4107–12; c) Vullo D, Nishimori I, Scozzafava A, Supuran CT. Carbonic anhydrase activators: activation of the human cytosolic isoform III and membrane-associated isoform IV with amino acids and amines. Bioorg Med Chem Lett 2008;18:4303–7.

26. a) Innocenti A, Hilvo M, Parkkila S, et al. Carbonic anhydrase activators. Activation of the membrane-associated isozyme XV with amino acids and amines. Bioorg Med Chem Lett 2009;19:3430–3; b) Supuran CT, Dinculescu A, Balaban AT. Carbonic anhydrase activators. Part 5. CA II activation by 2,4,6-trisubstituted pyridinium cations with 1-(α-aminoalkyl) side chains. Rev Roum Chim 1993;38:343–9; c) Supuran CT, Barboiu M, Luca C, et al. Carbonic anhydrase activators. Part 14. Synthesis of mono- and bis-pyridinium salt derivatives of 2-amino-5-(2-aminoethyl)- and 2-amino-5-(3-amino-propyl)-1,3,4-thiazole, and their interaction with isozyme II. Eur J Med Chem 1996;31:597–606; d) Ilies MA, Banciu MD, Ilies M, et al. Carbonic anhydrase activators. Part 17. Synthesis and activation study of a series of 1-(2,4-triazole-(1H)-3-yl)2,4,6-trisubstituted-pyridinium salts against isozymes I, II and IV. Eur J Med Chem 1997;32:911–8.

27. a) Ilies M, Banciu MD, Ilies MA, et al. Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties. J Med Chem 2002;45:504–10; b) Dave K, Scozzafava A, Vullo D, et al. Pyridinium derivatives of histamine are potent activators of cytosolic carbonic anhydrase isoforms I, II and VII. Org Biomol Chem 2011;9:2790–800; c) Dave K, Ilies MA, Scozzafava A, et al. An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isozyme II. Bioorg Med Chem Lett 2011;21:2764–8.

28. a) Scozzafava A, Supuran CT. Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. Bioorg Med Chem Lett 2002;12:1177–80; b) Scozzafava A, Supuran CT. Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold. J Med Chem 2002;45:284–91; c) Abdo MR, Vullo D, Saada MC, et al. Carbonic anhydrase activators: activation of human isozymes I, II and IX with phenylsulfonylhydrazido I-histidine derivatives. Bioorg Med Chem Lett 2009;19:2440–3; d) Saada MC, Montero JL, Vullo D, et al. Carbonic anhydrase activators: gold nanoparticles coated with derivatized histamine, histidine, and carnosine show enhanced activatory effects on several mammalian isoforms. J Med Chem 2011;54:1170–7; e) Zhang Y, Legrand YM, Petit E, et al. Dynamic encapsulation and activation of carbonic anhydrase in multivalent dynamic host matrices. Chem Commun (Camb) 2016;52:4053–5.

29. a) Vullo D, De Luca V, Scozzafava A, Carginale V, Rossi M, Supuran CT, Capasso C. The first activation study of a bacterial carbonic anhydrase (CA). The thermostable z-CA from Sulphurmonoglobium yellowstonense YO3A0P1 is highly activated by amino acids and amines. Bioorg Med Chem Lett 2012;22:6324–7; b) Innocenti A, Zimmerman SA, Scozzafava A, Ferry JG, Supuran CT. Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines. Bioorg Med Chem Lett 2008;18:6194–8; c) Vullo D, Del Prete S, Osman SM, et al. Comparison of the amine/amino acid activation profiles of the β- and γ-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei. J Enzyme Inhib Med Chem 2018;33:25–30; d) Vullo D, Del Prete S, Osman SM, et al. Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines. Bioorg Med Chem Lett 2017;27:77–80; e) Angeli A, Del Prete S, Osman SM, et al. Activation studies of the γ-carbonic anhydrases from the antarctic marine bacteria Pseudoalteromonas haloplankis and Colwellia psychrerythraea with amino acids and amines. Marine Drugs 2019;17:238–47;

30. a) Canto de Souza L, Provensi G, Vullo D, et al. Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus. Neuropharmacology 2017;118:148–56; b) Wang X, Schröder HC, Schlossmacher U, et al. Modulation of the initial mineralization process of SaOS-2 cells by carbonic anhydrase activators and polyphosphate. Calif Tissue Int 2014;94:495–509; c) Sanku RKK, John JS, Ilies MA, Walker EA. Potential learning and memory disruptors and enhancers in a simple, 1-day operant task in mice. Behav Pharmacol 2018;29:482–92.

31. a) Monti SM, Meccariello A, Ceruso M, et al. Inhibition studies of Brucella suis β-carbonic anhydrases with a series of 4-substituted pyridine-3-sulphonamides. J Enzyme Inhib Med Chem 2018;33:255–9; b) Ombouma J, Vullo D, Köhler S, et al. N-glycosyl-N-hydroxysulfamides as potent inhibitors of Brucella suis carbonic anhydrases. J Enzyme Inhib Med Chem 2015;30:1010–2;

32. a) Riafrecha LE, Vullo D, Ouahrami-Bettache S, et al. Inhibition of β-carbonic anhydrases from Brucella suis with C-cinnamoyle glycosides incorporating the phenol moiety. J Enzyme Inhib Med Chem 2015;30:1017–20; b) Riafrecha LE, Vullo D, Supuran CT, Colinas PA. C-glycosides incorporating the 6-methoxy-2-naphthyl moiety are selective inhibitors of fungal and bacterial carbonic anhydrases. J Enzyme Inhib Med Chem 2015;30:857–61; c) Maresca A, Scozzafava A, Köhler S, et al. Inhibition of beta-carbonic anhydrases from the bacterial pathogen Brucella suis with inorganic anions. J Inorg Biochem 2012;110:36–9.

33. a) Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34; b) Supuran CT. Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs. Curr Med Chem 2012;19:831–44;

34. a) Stefanucci A, Angeli A, Dimmito MP, et al. Activation of β- and γ-carbonic anhydrases from pathogenic bacteria with tripeptides. J Enzyme Inhib Med Chem 2018;33:945–50;
b) Angeli A, Buonanno M, Donald WA, et al. The zinc - but not cadmium - containing \( \alpha \)-carbonic from the diatom *Thalassiosira weissflogii* is potently activated by amines and amino acids. *Bioorg Chem* 2018;80:261–5; c) Angeli A, Donald WA, Parkkila S, Supuran CT. Activation studies with amines and amino acids of the \( \alpha \)-carbonic anhydrase from the pathogenic protozoan *Leishmania donovani chagasi*. *Bioorg Chem* 2018;78:406–10; d) Angeli A, Del Prete S, Donald WA, et al. The \( \gamma \)-carbonic anhydrase from the pathogenic bacterium *Vibrio cholerae* is potently activated by amines and amino acids. *Bioorg Chem* 2018;77:1–5.

Nguyen GTH, Tran TN, Podgorski MN, et al. Nanoscale ion emitters in native mass spectrometry for measuring ligand-protein binding affinities. *ACS Cent Sci* 2019;5:308–18.